<DOC>
	<DOC>NCT01990469</DOC>
	<brief_summary>After a screening, a 2-week, single-blind placebo run-in, 174 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Gemigliptin 50 mg or placebo to ongoing stable doses of glimepiride in combination with metformin for 24 weeks.</brief_summary>
	<brief_title>Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin</brief_title>
	<detailed_description>Subjects will visit the center on Week 6, 12, 18 and 24 during the entire 24-week treatment period. Total study duration will be approximately 26weeks and the subjects will be to practice exercise/diet control together.</detailed_description>
	<criteria>1. Patients with Type 2 Diabetes Mellitus 2. Adults aged â‰¥ 19 years old 3. Patients with HbA1c 7%~11% at Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>